Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Labcorp forecasts upbeat annual profit on strong demand for diagnostic products
Labcorp forecasts upbeat annual profit on strong demand for diagnostic products
The logo for Labcorp, Laboratory Corporation of America, a life sciences company is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., June 22, 2023. REUTERS/Brendan McDermid · Reuters
Reuters
Tue, February 17, 2026 at 10:00 PM GMT+9 1 min read
In this article:
LH
+1.63%
Feb 17 (Reuters) - Laboratory services provider Labcorp forecast annual profit above Wall Street estimates on Tuesday, banking on robust demand for its diagnostic tests.
Steady demand for non-urgent surgeries, especially among older Americans, has been boosting the business of companies such as Labcorp over the past few quarters.
The North Carolina-based company expects its diagnostic segment to grow between 5% and 6% in 2026.
It expects its annual adjusted profit per share to be between $17.55 and $18.25, with the midpoint above analysts’ average estimate of $17.50, according to data compiled by LSEG.
“We expect continued strong performance in 2026 as we remain focused on growth,” CEO Adam Schechter said in a statement.
Labcorp expects its annual revenue in the range of $14.61 billion to $14.79 billion, while analysts estimate $14.63 billion.
“Overall, we see this print giving Labcorp the ability to continue its steady growth, supported by a healthy end market that also saw outperformance from peer Quest Diagnostics,” said Leerink Partners analyst Michael Cherny.
Over the past year, Labcorp and Quest have benefited from agreements to manage hospital laboratories, which helped them expand their market share.
Labcorp also beat fourth-quarter profit estimates, helped by steady demand in its diagnostics and central laboratory businesses.
The company posted adjusted profit of $4.07 per share for the three months ended December 31, compared with the estimate of $3.94 per share.
Sales at its biopharma laboratory services segment, which offers contract research facilities for biopharmaceutical companies, rose 3.4%, while the diagnostics business grew 5.5% during the period.
Labcorp’s total quarterly sales were at $3.52 billion, compared with the estimate of $3.56 billion.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Shilpi Majumdar)
Terms and Privacy Policy
Privacy Dashboard
More Info